Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Multicenter Study, of Combination Anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease)

NCT04128319 is registered in ClinicalTrials.gov with Xenikos as lead sponsor.

NCT NCT04128319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04128319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Multicenter Study, of Combination Anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease)
Lead sponsor
Xenikos
Phase
Phase 3
Overall status
Terminated
Start date
November 21, 2019
Completion date
February 17, 2020
Enrollment
3 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-refractory acute graft versus host disease